trial

Minocycline for the Treatment of Early-Phase Schizophrenia

NCTId NCT00733057
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 70 (actual)
Sponsored by Shalvata Mental Health Center
Primary completion 2007-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2003-08
Primary completion
2007-03
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Minocycline

Sponsors

Shalvata Mental Health CenterLead Sponsor
Abarbanel Mental Health CenterCollaborator

Investigators

1
Yechiel - Levkovitz, M.D. PhD.Principal Investigator

Sites

1 total
Hod HaSharon, Israel

Linked catalysts

1
Minocycline for the Treatment of Early-Phase Schizophrenia — primary completion2007-03

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE3
Primary Completion Date
2007-03
Status
COMPLETED
relationships
The graph out of here
drug
Minocycline
drug
lead_sponsor
Shalvata Mental Health Center
company
collaborator
Abarbanel Mental Health Center
company
indication
Negative and Cognitive Symptoms in Schizophrenia
indication
Schizophrenia
indication
cyclopia sequence
indication
investigator
Yechiel - Levkovitz, M.D. PhD.
person